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Introduction
Recognition of tumor cells by the immune system is essential 
for effective antitumor immune responses. Although it has been 
well established that the immune system is capable of recognizing 
tumor-specific antigens and eradicating malignant cells, the opti-
mal method for harnessing the immune response against cancer 
remains elusive. The process is indeed complex and involves the 
orchestrated activities of innate and acquired immunity.
Natural killer (NK) cells are lymphocytes of the innate 
immune system which play a key role in the defense against 
tumors and viral infections. NK cell activation resulting in target 
cell lysis and/or cytokine and chemokine production is mediated 
by various activating receptors. These include NKp46, NKp30 
and NKp44, collectively termed natural cytotoxicity recep-
tors (NCRs).1,2 NCRs are unique to NK cells with NKp46 and 
NKp30 being expressed on both resting and activated NK cells 
and NKp44 being expressed only upon activation.1,2 Of note, 
only NKp46 is expressed in mice. Endogenous ligands for these 
activating receptors are mostly unknown, although viral ligands 
have been defined.3 A strong correlation between the density of 
NCR expression and the ability of NK cells to kill target cells, 
including a wide variety of tumor cells, has been identified.4 
A role for NKp46 in antitumor immunity has been shown, as 
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the use of anti-NKp46 blocking antibodies inhibited the abil-
ity of NK cells to lyse targets,5 although the cellular ligand for 
NKp46 is unknown. On the other hand, influenza (A/PR/8/34) 
haemagglutinin (HA) and the haemagglutinin-neuraminidase 
(HN) of Sendai virus have been shown to trigger NKp46 sig-
naling through binding of threonine at position 225, via α2, 
6-linked sialic acid in the membrane proximal domain of the 
molecule.3,6 NKp44 has been shown to trigger NK activation in 
response to the same ligands, via similar mechanisms.7 Viruses, 
in particular RNA paramyxoviridae, are being used as potential 
therapies for cancer. In particular, vaccines derived from viruses 
are being used to provide “danger” signals which would allow/
enhance immune responses to tumor-associated antigens. These 
viral “danger” signals were found to induce both innate and 
adaptive immune responses, and promising antitumor activity 
was observed (reviewed in ref. 8).
NK activation has been shown to influence adaptive immune 
responses, predominantly through interaction with dendritic 
cells (DCs). Initial reports of the NK-DC interaction focused on 
NK activation by DCs. Both cytokine production by DC, which 
includes interleukin (IL)-12/IL-18, IL-15 and Type 1 interfer-
ons, as well as the direct contact between DCs and NK cells, 
have been shown to be required for DC-mediated NK cell acti-
vation.9 Once activated by DC, NK cells can mediate primary 
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adaptive immune responses and provides pro-
tection to mice against subsequent challenges 
with cancer cells. This strategy therefore pro-
vides a strong basis for the development of 
novel anticancer immunotherapy protocols.
Results
HN expression on tumor cells enhances 
lysis by NK cells and production of IFNγ. 
NK cell activation through NKp46 engage-
ment is important in mediating tumor cell 
lysis in vivo,17-19 however, the tumor cell tar-
gets are unknown. We therefore explored 
whether the expression use of viral antigens, 
known to engage NKp46, by tumor cells 
would facilitate NK cell activation and cancer 
cell lysis. B16.OVA tumor cells were trans-
fected with the haemagglutinin-neuramini-
dase (HN) gene from the mumps virus and 
assessed for sensitivity to NK-cell mediated 
lysis. Stable transfection of B16.OVA with 
HN failed to generate long-term expressing 
clones, with HN expression being lost after 
96 h despite survival in antibiotic selection 
medium. Therefore, transient transfection 
was employed. Transfection efficiency of 
B16.OVA was assessed by flow cytometry 
prior to each experiment and was typically 
15–25%. NK mediated lysis of B16.OVA 
cells transfected with HN (B16.OVA-HN) 
was significantly greater than that of B16.
OVA cells transfected with an vector (B16.
OVA-SR
α
) (40% compared with 20% at 10:1 
effector:target ratio; Fig. 1A and B), indicat-
ing the ability of HN to enhance tumor cell 
lysis. As an additional validation of NK acti-
vation, the ability of HN-expressing tumor 
cells to induce production of IFNγ by NK 
cells was assessed. NK cells incubated with 
B16.OVA-HN cells induced a greater number of IFNγ-producing 
cells compared with B16.OVA-SR
α
 (Fig. 1C), confirming the 
ability of HN to enhance NK responses to tumor cells.
NK cell activation by HN expressing tumor cells is depen-
dent on NKp46. NK cell activation is governed by the balance 
between activating and inhibitory receptors, with the latter pre-
dominating in normal homeostasis. Following the increase in 
activation seen with HN-expressing tumor cells, we sought to 
identify the interactions that would be responsible for this phe-
nomenon. A candidate NK activating receptor which responds 
to HN is NKp46, an NCR found only on NK cells, which has 
been shown to bind to viral haemagglutinin.3,6,20 We first investi-
gated whether NKp46 bind HN expressed on tumor cells using 
immunoglobulin (Ig)-fusion constructs. NKp46-Ig incubated 
with B16.OVA-HN revealed binding to HN-expressing tumor 
cells, which was not observed when the unrelated NK receptor 
tumor rejections.10 The NK-DC interaction was found to be bi-
directional and complex. Indeed, activated NK cells can induce 
DC maturation by producing cytokines including interferon γ 
(IFNγ) and tumor necrosis factor α (TNFα) 11,12 and/or upon 
direct cell-cell contact,13 and can promote the generation of CD8+ 
T cell memory responses.14 Conversely, NK cells are capable of 
killing immature DCs by virtue of the low expression of NKG2A 
ligand (HLA-E) on immature DCs, and NK-cell activation via 
NKp30.15,16
In this study we investigated the immunological effects of 
tumor cells expressing HN derived from mumps virus and its 
ability to enhance antitumor immune responses in vivo. Our 
data demonstrate that HN expression on tumor cells enhances 
NK cell activation and induces DC maturation. We also show 
that NK cell and DC activation is further stimulated through 
the NK-DC crosstalk, which enables the generation of robust 
Figure 1. hN expression by B16.OVa tumor cells enhances NK cell responses. (A) Specific lysis 
of B16.OVA cells transfected with HN derived from mumps virus (•) or an empty vector (○) 
following incubation with syngeneic NK cells at effector:target ratios from 30:1 to 1.25:1. (B) 
Specific lysis of B16.OVa-hN, B16.OVa-SR
α
, B16.OVa or (class I Mhc-negative) RMa-S cells incu-
bated with NK cells at a 10:1 effector:target ratio. ***p < 0.001, B16.OVa-hN cells in comparison 
with B16.OVa-SR
α
 or B16.OVa cells. (C) The production of IFNγ was assessed by eLISpot fol-
lowing incubation of NK cells alone or with B16.OVa-SR
α
, B16.OVa-hN cells for 24 h. **p < 0.01, 
*p < 0.05, B16.OVa-hN + NK cells in comparison to B16.OVa-SRα + NK cells and both compared 
with NK only. p values were calculated with two tailed Student’s t-tests.
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resulted in the highest amount of IFNγ production (Fig. 4B). 
By contrast, separation of the cells resulted in significantly 
lower IFNγ production. These results suggest that cell-to-cell 
contacts and synapse formed between DCs and NK cells are 
essential to enhance IFNγ production by NK cells. This fits 
KIR2DS4-Ig fusion was used (Fig. 2A and B). Interestingly, 
there was also low level of NKp46-Ig binding to B16.OVA 
cells, consistent with previous work suggesting the existence 
of currently unidentified NKp46 ligands on tumor cells.7,21 
We next investigated whether the interaction between HN 
and NKp46 is required for the activation of NK cells. B16-
OVA-HN cells incubated with NKp46-Ig were lysed by NK 
cells much less (~50%) than cells incubated with control Igs. 
The inhibition provided by NKp46-Ig was reduced as the 
amount of NKp46-Ig was reduced (Fig. 2C). In addition, 
no inhibition of NK-mediated lysis was observed when B16.
OVA cells were incubated with NKp46-Ig (data not shown), 
indicating that the predominant mechanism underlying 
NK-mediated lysis was the interaction between NKp46 and 
HN. Failure to obtain complete inhibition with NKp46-Ig 
perhaps was due to the use of sub-saturating amounts of 
NKp46-Ig or to the involvement of other NK activating 
receptors.21
Induction of DC maturation and IL-12 production by 
tumor cells expressing HN. HN and other viral antigens 
have been shown to exert varying effects on the immune 
response. Thus, measles virus-derived HA inhibits DC acti-
vation22 whereas, influenza virus-derived HA incorporated 
into virus like particles promotes DC activation and the 
release of Th1 cytokines.23 In addition, the neuraminidase 
activity of human parainfluenza 3 virus-derived HN induces 
DC maturation and activation.24 Having demonstrated the 
effect of HN expression on NK cell activation and lysis of 
tumor cells, we investigated the effect of HN-expressing 
tumor cells on antigen-presenting cells (APCs) such as DCs. 
Incubation of B16-OVA-HN cells with DCs resulted in the 
upregulation of the activation/maturation markers Class II 
MHC, CD80 and CD86, whereas incubation of DC with 
B16-OVA cells failed to do so (Fig. 3A). To confirm DC 
activation, we investigated the production of the key Th1 
cytokine IL-12, following incubation with B16.OVA-HN 
cells. Both the number of DCs producing IL-12 and the 
amount of IL-12 produced were significantly increased 
when DCs were incubated with B16.OVA-HN, while incu-
bation with B16-OVA-SR
α
 or B16-OVA cells resulted in no 
increase (Fig. 3B and C).
Co-incubation of NK Cells and DCs with 
HN-expressing tumor cells leads to enhanced IFNγ 
production. With the observation that both NK cells 
and DCs are activated by tumor cells expressing HN, we 
investigated whether HN induces a functional crosstalk 
between NK cells and DCs. HN or SR
α
-transfected tumor 
cells were incubated with NK cells, alone or plus DCs. 
The combination of NK, DC and B16.OVA-HN cells 
significantly increased the amount of IFNγ detected in 
culture supernatants to approximately twice the amount 
seen when NK cells and DCs were incubated with B16.OVA-
SR
α
 (Fig. 4A). We utilized trans-well plates in order to inves-
tigate the mechanisms behind this enhanced IFNγ release, 
and in particular to assess whether cell-to-cell contacts were 
important. Placing all three cell types in the same chamber 
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Figure 2. enhanced NK cell activation by hN is mediated by NKp46 engage-
ment. (A) B16.OVa-SR
α
 or B16.OVa-hN cells were incubated with NKp46-Ig 
or KIR2DS4-Ig for 30 min and assessed for binding by flow cytometry using 
an anti-human IgG. Data are representative of 3 experiments. (B) a represen-
tative histogram of KIR2DS4-Ig binding to B16.OVa-SR
α
 (dark gray) or B16.
OVa-hN (light gray) cells and NKp46-Ig binding to B16.OVa-SR
α
 (black) or 
B16.OVa-hN (dotted line) cells. (C) NK cells were incubated with B16.OVa-hN 
cells at a 10:1 effector:target ratio in the presence of KIR2DS4-Ig or NKp46-Ig. 
*p < 0.05, comparing KIR2DS4-Ig with NKp46-Ig at 640 mg/mL, p values were 
calculated with two-tailed Student’s t-tests.
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cells in vivo. B6 mice were vaccinated with B16.OVA-HN or 
B16.OVA-SR
α
 tumor cells and the percentage of activated NK 
cells assessed daily using the NK cell marker DX5 and activa-
tion marker CD69. Mice challenged with B16.OVA-HN cells 
exhibited increased percentage of activated (DX5+ and CD69+) 
NK cells (> 150%) as compared with animals challenged with 
B16.OVA-SR
α
 cells, peaking at day 2 after vaccination (Fig. 5). 
Tumor cells transfected with a control vector induced a mod-
est increase in activated NK cells (~30%). These data confirm 
that HN-expressing tumor cells are able to induce more robust 
NK activation in vivo than tumor cells alone. We next inves-
tigated whether B16.OVA-HN cell vaccination would induce 
protective immunity against a subsequent challenge with B16.
OVA cells. B6 mice were vaccinated with 2 × 105 irradiated 
B16.OVA-HN or B16.OVA tumor cells on days 0 and 7. On day 
14, mice were challenged with 1 × 105 living B16.OVA cells. 
Strikingly, mice vaccinated with B16.OVA-HN tumor cells 
were better protected against a subsequent challenge with B16.
OVA cells than mice receiving irradiated B16.OVA cells as well 
as than non-vaccinated mice (Fig. 6A). Since B16.OVA-HN 
cell vaccination enabled robust protection against B16.OVA 
cells, we examined which cells were important for this immu-
nity. Depletion of NK cells during B16.OVA-HN vaccination 
with the model by which transfer of pre-assembled stores of 
IL-12 from DCs to NK cells enhances IFNγ release by NK 
cells.25 To assess the importance of DC-derived IL-12 in this 
response, we repeated the incubation of B16.OVA-HN cells, 
NK cells and DCs in the presence of an anti-IL-12 blocking 
antibody. Addition of the blocking antibody induced a signifi-
cant reduction in IFNγ, to a level equivalent to that observed 
in the presence of NK cells and DCs only (Fig. 4C). To fur-
ther confirm the role of IL-12 in enhancing NK cell activation 
and IFNγ production, B16.OVA-HN and B16.OVA cells were 
transfected with an IL-12 expression plasmid. Incubation of 
NK cells with these IL-12 expressing tumor cells resulted in 
a significant increase (20 to 25-fold) in the amount of IFNγ 
produced, which was greatest when B16.OVA-HN were used 
(Fig. 4D). This confirms the importance of IL-12 provided by 
DCs in enhancing NK cell activation. Taken together, these 
results suggest a mechanism of crosstalk between NK cells and 
DCs which serves to enhance NK cell cytotoxicity and cyto-
kine production as well as DC activation following exposure to 
HN expressed on tumor cells.
HN-expressing tumor cells induce an increase in circu-
lating NK cells following in vivo challenge. We next inves-
tigated whether HN-expressing tumor cells could activate NK 
Figure 3. hN-expressing B16.OVa cells induce Dc maturation. Dcs were incubated alone or with LpS, B16.OVa, B16.OVa-SR
α
 or B16.OVa-hN cells for 
24 h and cD11c+ cells were then assessed for; (A) expression of Dc maturation markers class II Mhc (left part), cD80 (center part) and cD86 (right part) 
by flow cytometry (data are representative of three experiments) and IL-12 production by intracellular cytokine staining (B) or eLISa (C). **p < 0.01, 
comparing B16.OVa-hN cells with B16.OVa-SR
α
 or B16.OVa cells, p values were calculated with two-tailed Student’s t-tests.
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T cells. As DCs are “licensed” through engagement with CD4+ 
T cells, we investigated the role of CD4+ T cells in the anti-B16.
OVA response. Mice vaccinated with B16.OVA-HN cells and 
then challenged with B16.OVA cells were depleted of CD4+ T 
cells either throughout the entire experiment or at the point of 
tumor challenge. CD4+ T cell depletion did not affect the ability 
to induce robust anti-B16.OVA responses (Fig. 7C). This result 
suggests that CD4+ T cell responses plays a critical role neither 
during the priming phase (αCD4) nor during the acute effector 
phase (αCD4-effector).
prevented tumor rejection and 
resulted in tumor development at the 
same rate as naïve B16.OVA cell-chal-
lenged animals (Fig. 6B). In addition, 
depletion of CD8+ T cells at the time 
of the B16.OVA challenge abrogated 
tumor protection with a median sur-
vival time similar to naïve controls 
(Fig. 6B). These results indicate that, 
in this setting, antitumor protection 
is mediated by both NK and CD8+ T 
cells.
B16.OVA-HN cell vaccination 
does not induce long-term immu-
nity. In order to examine whether B16.
OVA-HN cell vaccination induced 
long-term protective immunity to B16.
OVA cells, mice protected from the 
initial B16.OVA challenge were rechal-
lenged 4 weeks later and their ability 
to reject the tumor assessed. B16.OVA-
protected mice challenged with either 
B16.OVA or B16 tumor cells showed an 
increase in median survival time (16.5 
and 23 d respectively) compared with 
naïve controls (15 d) (Fig. 7A). Of note, 
the protection from tumor challenge 
was only seen in 1/8 mice, indicating 
that the initial B16.OVA-HN vaccina-
tion may not be sufficient to generate 
a long-term memory response to B16- 
or OVA-derived antigens. Failure to 
generate long-term immunity suggests 
that the initial anti-B16.OVA response 
did produce effector CD8+ T cells that 
efficiently eradicated the tumor, but 
not a CD8+ T-cell memory popula-
tion. Inability to generate memory 
CD8+ T cells has been linked with the 
costimulatory molecule CD27 and its 
ligand CD70.26,27 DCs play a major 
role in both the activation of naïve 
CD8+ T cells and their differentiation 
into memory cells in vivo, and CD70 
blockade at priming impairs memory 
T-cell responses.28 We therefore inves-
tigated whether the activation of DCs by B16.OVA-HN tumor 
cells in the presence of NK cells induces CD70 expression. DCs 
cultured with B16.OVA-HN tumor cells plus NK cells did not 
upregulate expression of CD70 although CD70 expression was 
induced on DCs when incubated with soluble CD154 and CpG 
oligonucleotides (Fig. 7B). This suggests that despite inducing 
a robust antitumor CD8+ T cell response, the lack of CD70 on 
DCs at priming prevents the differentiation of memory T cells. 
The ability of DCs to prime naïve CD8+ T cells indicates that 
they were “licensed,” but not fully competent to induce memory 
Figure 4. The NK-Dc crosstalk further enhances hN-mediated activation of NK cells. (A) NK cells were 
incubated alone or with B16.OVa-SR
α
 or B16.OVa-hN cells in the presence or absence of Dcs at a ratio 
of 2 B16.OVa cells:1 NK cell: 4 Dcs for 24 h and assessed for IFNγ production. ***p < 0.001, **p < 0.01, 
comparing B16.OVa-hN + NK + Dc with B16.OVa-hN + NK and B16.OVa-SR
α
 + NK + Dc, or B16.OVa-
SR
α
 + NK + Dc with B16.OVa-SR
α
 + NK, ND = Not detectable. (B) B16.OVa-hN, NK cells and Dcs were 
incubated in transwell plates with a different cell type placed in the insert and supernatants assessed 
for IFNγ. as a positive control B16.OVa-hN, cells NK cells and Dcs were co-cultured. (C) NK cells and 
Dcs were incubated with B16.OVa-hN cells in the presence or absence of a neutralizing anti-IL-12 or 
control antibody and assessed for IFNγ production. ***p < 0.001, **p < 0.01, comparing B16.OVa-hN 
+ NK + Dcs to B16.OVa-hN + NK + Dcs + αIL-12 and NK + Dcs. (D) NK cells were incubated with B16.
OVa-hN cells, IL-12 expressing B16.OVa cells or IL-12 expressing B16.OVa-hN cells. The production of 
IFNγ was assessed in all experiments. **p < 0.01, *p < 0.05 comparing, B16.OVa-hN cells with B16.OVa-
IL-12 cells or B16.OVa-hN-IL-12 cells, or comparing B16.OVa-hN-IL-12 cells with B16.OVa-IL-12 cells, p 
values were calculated with two tailed Student’s t-tests.
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expansion with IL-2 and reinfusion is well tolerated in patients 
and although NK cells have showed low cytotoxicity against 
tumor cells in early studies,30-32 more recently strong antitumor 
responses have been demonstrated.33-35
The expression of HN by tumor cells induced activation of 
NK cells and DC maturation toward a DC1 profile (IFNγ and 
IL-12 production). Interestingly, incubation of NK cells and 
DCs together with HN-expressing tumor cells enhanced IFNγ 
production by NK cells, an effect that was IL-12-dependent 
and required cell-to-cell contacts. This DC/IL-12-dependent 
improvement in NK cell activation is consistent with the NK-DC 
crosstalk mechanism. The NK-DC crosstalk is bi-directional, 
with activated NK cells inducing DC maturation by cytokine 
production and direct cell-to-cell contact.36 Direct interactions 
between DCs and NK cells also coordinate immune responses. 
Formation of a stimulatory synapse between activated NK cells 
and DCs promotes the polarized secretion of preassembled stores 
of IL-12 by DCs, which acts on NK cells. IL-12 is required for 
IFNγ production by NK cells, creating a positive feedback loop 
influencing cell mediated immunity.25 The DC-NK synapse is 
also required for NK cell-mediated cytotoxicity.11 The NK-DC 
cooperation has previously been documented in tumor mod-
els.14 T cell-mediated tumor rejection of A20 B-cell lymphoma 
cells was dependent on DC activation by NK cells, with IFNγ 
secreted during NK-cell mediated tumor rejection being critical 
for the generation of antitumor CTLs.
Vaccination of B6 mice with HN-expressing B16.OVA tumor 
cells induced robust protection against a subsequent challenge 
with living B16 or B16.OVA cells (> 85% survival). This indi-
cates that the immunity induced in the initial vaccination was 
directed toward B16-specific rather than HN- or OVA-specific 
antigens. Surprisingly, despite this strong initial protection, the 
majority of mice were not protected against a subsequent chal-
lenge with B16 or B16.OVA tumor cells, pointing to a failure in 
the generation of antigen-specific memory T cells. This inability 
to generate strong secondary memory responses in the B16 tumor 
model system has previously been demonstrated. One study 
investigating the generation of immune responses against B16 
cell-based vaccines reported a robust primary immune response, 
but not an effective memory response.37 An effective memory 
response was only generated when a CD40L-expressing plasmid 
was included in the vaccination. This indicates that the engage-
ment of DCs in the priming or effector phase of CD8+ T cells 
influences the differentiation of B16-specific memory T cells. 
The factors that allow for the induction of CD8+ T cell memory 
cells are poorly understood, but a role for epitope density has 
recently been shown.38 CD4+ T-cell help is also important for the 
generation, survival and functional responsiveness of long-lived 
memory CD8+ T cells.39 Fernandez et al. found that, depend-
ing on the nature of the initial stimulation, effective cytotoxic 
CD8+ T cells could be generated but they were short lived, and 
no functional memory CTLs were detected unless a source of 
CD4+ T-cell help was provided. Interestingly, the NK-DC cross-
talk may serve to bypass the function of CD4+ T-help in CTL 
induction against some tumors.10 In our experiments, we have 
not identified a role for CD4+ T cells in the B16.OVA response, 
Discussion
We have examined the effect of expressing paramyxoviral 
(mumps) HN in a murine tumor model. We show that HN has an 
effect on both NK cells and DCs. HN is a ligand for the activating 
NK cell receptor NKp46, and we demonstrate that the interac-
tion between HN and NKp46 results in enhanced NK-mediated 
killing of HN-transfected tumors and increased IFNγ produc-
tion by activated NK cells. Furthermore, HN-expressing cells 
promote DC maturation and stimulate them to produce IL-12. 
When DC sand NK cells are cultured with B16.OVA-HN cells, 
activation of NK cells is further boosted by a mechanism that 
requires cell-to-cell contact. Importantly, we demonstrate that 
vaccination with B16.OVA-HN cells protects mice against a 
subsequent challenge with the parental B16.OVA cells (> 85%). 
This protection is dependent on both innate (NK) and adaptive 
(CD8+ T cells) immune responses. These results show that the 
combined effects of direct NK activation by HN-expressing B16.
OVA cells and enhanced NK-DC crosstalk enables protection 
against the parental (non-HN-expressing) tumor.
Strategies aimed at increasing or activating the NK cell 
compartment have been attempted in cancer patients. Initial 
approaches used low dose IL-2 to selectively manipulate NK cells 
in patients with a range of metastatic tumors, leading to preferen-
tial stimulation of NK cells.29 Another approach was based on the 
ex vivo expansion and reinfusion of autologous NK cells. Ex vivo 
Figure 5. In vivo immunization of irradiated hN-expressing B16.OVa 
cells increases circulating activated NK cells. B6 mice were immunized 
with irradiated B16.OVa-SR
α
 (○) or B16.OVA-HN (•) cells (n = 9/group) 
and the percentage of circulating activated NK cells (cD49b+ and 
cD69+) was assessed from tail bleeds on days -1, 1, 2, 3 and 6 by flow 
cytometry. Data are reported as mean percentage ± SeM for each time 
point. ***p < 0.001, comparing B16.OVa-hN cells to B16.OVa-SRα cells 
on day 2 after vaccination using two-way aNOVa with Bonferroni cor-
rection test.
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incubation of NK, DC and HN-expressing tumor cells substan-
tially enhanced NK activation. The ability of these NK cells to 
facilitate tumor rejection in vivo indicates the benefit of HN in 
stimulating not only innate but also adaptive immune responses. 
Thus, our vaccine strategy may provide a novel adjuvant able to 
induce activation of both innate and adaptive immunity in vivo.
Materials and Methods
Cell analysis and transfection. For dendritic cell (DC) produc-
tion, murine bone marrow cells were harvested from femurs of 
C57BL/6 (B6) mice and plated out in a single-cell suspension 
in 100 ml RPMI medium (RPMI 1640 medium supplemented 
with 10% heat-inactivated FCS, 1 mM sodium pyruvate, 2 mM 
l-glutamine, 25 mM HEPES buffer and 50 μM 2-ME) in 6 well 
tissue culture plates (6 ml/well). GM-CSF was added at 20 ng/ml 
and the cells incubated at 37°C for 7 d. NK cells were isolated 
from spleens taken from B6 mice using biotinylated anti-CD49b 
(DX5) antibody (BD biosciences, 553856) together with the 
CELLection Biotin Binder Kit (Life technologies, 115-33D). NK 
cells were resuspended at 2 × 106 cells/ml in DMEM medium 
(DMEM with 10% FCS, 100 U/ml penicillin and streptomy-
cin, 1 mM sodium pyruvate, 2 mM glutamine, 50 μM 2-ME) 
containing 1,000 U rIL-2/ml (Peprotech, 212-12) in a 96-well 
U-bottomed plate and incubated at 37°C for 4 d.
The murine melanoma stably transfected with OVA, B16.
OVA, were maintained as previously described in reference 
41. B16.OVA cells were transfected with pcDL-SRα296-HN 
encoding recombinant HN derived from mumps virus, pcDL-
SRα296-IL-12 (encoding IL-12) or empty pcDL-SRα296 vec-
tor (a kind gift of Dr Y. Takebe, National Institute of Infectious 
Diseases, Japan) using Effectene transfection reagent (Qiagen) 
according to the manufacturers’ protocol. Efficiency of 
neither in the priming nor effector stage, however, as HN expres-
sion may support the NK-DC crosstalk, this does not exclude a 
role for CD4+ T-cell help in CD8+ memory T-cell differentiation 
in other B16 vaccine protocols.
The generation of a good T-cell memory response is also 
dependent on proper DC activation. DCs need to receive appro-
priate activation signals in order to become “licensed” to elicit 
both the efficient expansion of antigen-specific primary CD8+ 
T cell responses as well as the generation of memory T cells. 
“Licensing” can occur via CD4+ T cells or upon recognition 
of pathogen associated molecular patterns (PAMP).40 CD70 
expression on DCs and subsequent ligation of CD27 is required 
for CD8+ T-cell activation and the generation of an effective 
memory T-cell response.28 Blocking the CD70/CD27 interac-
tion in a primary response generated CD8+ T cells capable of 
lysing target cells, but incapable to expand following secondary 
challenge. Interestingly, despite the induction of DC matura-
tion by HN-expressing tumor cells, as measured by upregula-
tion of MHC Class II, CD80 and CD86, upregulation of CD70 
was not observed. It is therefore possible that the inability of 
HN to fully activate/mature DCs prevents the differentiation 
of B16-specific CD8+ T-cell memory cells following challenge. 
The use of agonistic anti-CD27 antibody in combination with 
the B16.OVA-HN vaccine may provide sufficient activation of 
naïve CD8+ T cells to facilitate memory T-cell differentiation. 
The engagement of CD70/CD27 and other co-stimulatory mol-
ecules (CD40/CD40L and 4-1BB/4-1BBL) in the generation of 
long-term CD8+ T-cell memory populations is currently under 
investigation.
The use of HN to enhance antitumor immunity and allow 
for tumor rejection provides a novel strategy for harnessing 
the NK-DC crosstalk against cancer. HN-expressing tumor 
cells induced NK activation and DC maturation. Moreover, 
Figure 6. In vivo immunization of irradiated hN-expressing B16.OVa cells protects against B16.OVa tumor challenge. (A) B6 mice (n = 15/group) were 
immunized twice with irradiated B16.OVa (○) or B16.OVA-HN (•) cells on days -14 and -7 or left untreated (x). On day 0 all mice were challenged with 
B16.OVa cells and tumor development was assessed. (B) B6 mice (n = 15/group) were immunized using only B16.OVa-hN cells. In addition, three fur-
ther groups were injected with anti-NK (◆), anti-cD8 (◇) or irrelevant antibodies (○) during vaccination, left untreated (•) or unimmunized (x). At day 0, 
all mice were challenged with B16.OVa cells and tumor development assessed. **p < 0.01, p values were calculated using the log-rank test comparing 
B16.OVa-hN-immunized with B16.OVa-immunized mice (A). ***p < 0.0001, comparing NK or cD8+ T-cell-depleted with control mice (B).
www.landesbioscience.com OncoImmunology 881
international, 734-1560P) and incubated with DC and NK cells 
at 1:1:0.5 (B16:DC:NK) ratio. The above experiments were 
repeated separating NK cells and DC. Supernatant from the cul-
tures was harvested after 24 h for analysis.
Tumor challenge. B6 mice, bred in Southampton, were used at 
6–10 weeks of age. B16.OVA or B16.OVA-HN cells were irradiated 
(25 gy) and 2 × 105 cells injected into the flank of B6 mice on days 
-14 and -7. On day 0 mice were challenged with 2 × 105 B16.OVA 
into the opposite flank and monitored daily for tumor development. 
Mice were sacrificed when mean tumor diameter was > 10 mm. 
Animal welfare and experimentation were conducted in accordance 
with the United Kingdom Coordinating Committee for Cancer 
Research guidelines with approval from University of Southampton 
Ethical Committee and under UK. Home Office License.
transfection was assayed by flow cytometry using the HN spe-
cific antibody 3-1.42
To examine DC activation by NK and tumor cells, DC 
were co-cultured with HN or control plasmid expressing B16.
OVA for 24 hours and analyzed for the expression of activation/
maturation markers CD80, CD86, MHC Class II and CD70 
(BD biosciences, 553756, 553691, 553605 and 555286) with a 
FACSCalibur using CellQuest software (BD Biosciences). For 
CD70 experiments, a CD70 upregulators soluble CD154 and 5 
μg/ml CpG (oligonucleotide 1668) were used. In some assays 
LPS (Sigma-Aldrich) was used as a positive control for DC 
activation.
For transwell experiments, B16.OVA or B16.OVA-HN cells 
were plated out in the wells or inserts of transwell plates (VWR 
Figure 7. B16.OVa-hN immunization does not induce memory T-cell responses. (A) B6 mice (n = 8/group) that had rejected the B16.OVa tumor chal-
lenge were rechallenged with B16.OVA (•) or B16 (○) cells. In addition, naïve B6 mice (n = 8/group) were challenged with B16.OVa (◆) or B16 (x) cells. 
Mice were monitored for tumor development. (B) Dcs were incubated with B16.OVa and NK cells, B16.OVa-hN and NK cells, soluble cD154 or cpG 
oligonucleotides. cD11c+ cells were analyzed for cD70 expression by flow cytometry. Data are representative of four experiments. (C) B6 mice (n = 8/
group) were immunized with irradiated B16.OVA-HN cells and challenged with B16.OVA (•) cells as in Figure 6 or left untreated (x). In addition, two 
groups of mice (n = 8) were depleted of T cells either throughout the experiment (○; cD4) or at the time of B16.OVa challenge (◆; cD4-effector). Mice 
were monitored for tumor development.
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Following overnight incubation IFNγ was detected using 
biotinylated antibody XMG1.2. Streptavidin-AP (MabTech, 
3310-10) and substrate BCIP/NBT (Cambridge Bioscience, 
BCIB-0100-01) were used for detection and spots counted 
with an ELISpot reader and reported as the number of spots 
per 106 splenocytes.
For intracellular detection of IL-12, DC and HN transfected 
B16.OVA were incubated for 24 h and IL-12 production assessed 
using the Cytofix/Cytoperm Fixation/Permeabilization solution 
kit with Golgi Plug (BD biosciences, 555028). Anti-IL-12-FITC 
(BD biosciences, 560564) was used to detect IL-12 producing 
DC. Analyses were performed on CD11c+ DC populations.
Cytotoxicity assay. The cytolytic activity of NK cells against 
B16.OVA transfectants was assessed in a standard 4 h 51Cr-release 
assay in which effector cells were co-incubated with 5 × 103 
51Cr-labeled targets at a 10:1 E:T ratio. Spontaneous release was 
determined by incubation of labeled target cells with medium 
and maximal release determined by incubation of target cells 
with detergent (4% NP-40). % specific lysis was calculated as 
100 x [(cpm experimental well - cpm spontaneous release)/(cpm 
maximal release - cpm spontaneous release)]. For blocking exper-
iments, recombinant mouse NKp46-Ig chimera (R&D Systems, 
2225-NK-050) or human KIR construct (2DS4-Ig) were used. 
The Ig chimeras were included in cultures at a final concentra-
tion of 160–640 μg/ml. To prevent NK cell interaction with Fc 
region of the chimeras, either anti-mouse CD16/CD32 (BD bio-
sciences, 553141) was used (25 μg/ml) or targets were incubated 
in 50% mouse serum for 1 h before being introduced into the 
51Cr-release assay.
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NK cell detection and NK, CD8 and CD4 T cell depletion. 
B6 mice vaccinated as described above were monitored for circu-
lating NK cells using daily tail bleeds for 6 d. Erythrocytes were 
lysed using red cell lysis solution (Gentra, D-40K) and PBMCs 
analyzed by flow cytometry using anti-CD49b and anti-CD69 
(BD biosciences, 5538567 and 553237).
For depletion of NK and cells mice were injected with anti-
asialo GM1 antibody (Wako, 986-10001) or normal rabbit serum 
(Sigma-aldrich, R9133) as a control on days -17, -15, -8 and -1 
of the B16.OVA vaccination protocol described above. The effi-
ciency of NK cell depletion was confirmed by flow cytometry 
(anti-NK1.1-PE and anti-CD3-FITC; BD biosciences 553165 
and 553061). For CD8+ and CD4+ T cell depletion, anti-CD8 
(YTS169.4.2.1) or anti-CD4 antibodies (YTS191.1.2) were 
injected five times every 3 d starting at day-15. CD8 T cell 
depletion was confirmed by flow cytometry (anti-CD8-APC, 
anti-CD4-APC and anti-CD3-FITC; BD biosciences 553035 
and 553051) from tail bleeds. Control rat monoclonal antibody, 
Mc10-6A5 (anti-BCL1 Id mAb) was kindly provided by Dr M.J. 
Glennie, University of Southampton.
Detection of IFNγ and IL-12 producing cells. NK cells and/
or dendritic cells were incubated with B16.OVA transfected with 
HN or control plasmid DNA for 24 h. Blocking anti-IL-12 anti-
body (R&D Systems, AF-419-NA) was also added to cultures 
(10 μg/ml) to assess the role of IL-12 in the response. IFNγ and 
IL-12 was detected in the culture supernatants by ELISA. For 
detection of IFNγ the capture antibody R4-6A2 and the biotinyl-
ated detection antibody XMG1.2 (BD biosciences, 551216 and 
554410) were used. For IL-12, the antibodies 9A5 and biotinyl-
ated C17.8 were used for capture and detection respectively (BD 
biosciences, 554658 and 554476). Avidin-AP (Sigma-Aldrich, 
A7294) and pNPP substrate (Sigma-Aldrich, P5994) were detec-
tion and read at 405 nm (BioRad 680).
IFNγ production was also assessed by ELISpot. 
Multiscreen-IP 96-well plates (Millipore, S2EM004M99) were 
coated with capture antibody R4-6A2. NK cells were added to 
each well ± dendritic cells ± HN or control transfected B16.
OVA cells. Medium only and 0.5 μg/well of concanavalin 
A were used for negative and positive controls, respectively. 
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